Unknown NA INTERVENTIONAL NCT01676506

Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

The Impact of Genetic Polymorphisms on Ranibizumab Treatment Outcomes in Wet Age-Related Macular Degeneration (AMD)

Sponsor: Russian Academy of Medical Sciences

Conditions Age-Related Macular Degeneration

Interventions Ranibizumab Ranibizumab Injection

Updated 6 times since 2017 Last updated: Aug 30, 2012 Started: Oct 31, 2011 Primary completion: Oct 31, 2013 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Age-Related Macular Degeneration, this trial is ongoing. The trial is conducted by Russian Academy of Medical Sciences and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown NA
Sep 2024 — Sep 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Russian Academy of Medical Sciences

Data source: Russian Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia